Evaluation of Cutoff Point Prostate Specific Antigen (PSA) and Prostate Specific Antigen Density (PSAD) in Patients...

Area of Science:

• Urology
• Oncology
• Medical Diagnostics

Background:

• Prostate cancer is a leading cause of cancer death in men globally.
• Current lack of standardized PSA cut-off levels contributes to unnecessary prostate biopsies.
• Transrectal prostate biopsy carries risks of bleeding, infection, and sepsis.

Purpose of the Study:

• To establish precise Prostate Specific Antigen (PSA) and Prostate Specific Antigen Density (PSAD) cut-off points for patients with suspected prostate cancer.
• To provide data that can help clinicians avoid unnecessary prostate biopsies.

Main Methods:

• Retrospective study of 53 patients undergoing TRUS-guided prostate biopsy (January 2018 - March 2021).
• Inclusion criteria: suspected prostate cancer, age >50, PSA, PSAD, and biopsy data available.
• Statistical analysis included Mann-Whitney U, Chi-Square, Fisher's Exact, and ROC curves.

Main Results:

• Identified PSA cut-off level of 19.71 ng/ml (Sensitivity: 69.23%, Specificity: 72.5%).
• Identified PSAD cut-off level of 0.4113 (Sensitivity: 61.54%, Specificity: 63.16%).
• These determined cut-off levels are higher than previously recommended values.

Conclusions:

• The study determined specific PSA and PSAD cut-off levels for suspected prostate cancer.
• These findings suggest that current recommended cut-offs may be too low, potentially leading to unnecessary procedures.
• Establishing accurate cut-offs is vital for improving diagnostic accuracy and patient outcomes in prostate cancer screening.